Continuous glucose monitoring compared with fingerstick checks in adults with prediabetes
Tests a continuous glucose sensor against finger-prick checks in adults with prediabetes.
Plain-language title generated from the registry record
Registry title: PREdiabetes GLycemic Impact and Data Evaluation
Key facts
- Where
- Kyiv, UkraineSee the 3 sites
Where in Ukraine
- Bogomolets National Medical UniversityKyiv, UkraineTaking people
- Bogomoletz Institute of PhysiologyKyiv, UkraineEnrolling by invitation
- University Hospital of Bogomolets National Medical UniversityKyiv, UkraineTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Nazarii Kobyliak
- Trial code
- NCT07599072
- Record updated
- 29 September 2026
- Original description
This prospective, randomized controlled trial evaluates whether real-time continuous glucose monitoring (CGM) improves glycemic control and lifestyle adherence in adults with prediabetes compared to conventional self-monitoring methods over a 3-month period. By analyzing metabolic markers and behavioral data, the study aims to determine the effectiveness of 24-hour monitoring as a personalized tool that increases patient adherence to lifestyle changes compared to conventional SMBG methods.Read full original descriptionShow less
Evaluation of the Impact of Continuous Glucose Monitoring (CGM) Systems on Glycemic Control in People With Prediabetes: Postmarketing Clinical Study
This prospective, randomized controlled trial evaluates whether real-time continuous glucose monitoring (CGM) improves glycemic control and lifestyle adherence in adults with prediabetes compared to conventional self-monitoring methods over a 3-month period. By analyzing metabolic markers and behavioral data, the study aims to determine the effectiveness of 24-hour monitoring as a personalized tool that increases patient adherence to lifestyle changes compared to conventional SMBG methods.
Inclusion: Age of 18 years and older; Presence of prediabetes diagnosed according to criteria of the American Diabetes Association; Persons who treated with diet and exercise alone or metformin on a stabilized dose for at least 3 months before the study; Ability to comply with protocol requirements and maintain a patient diary; Signed informed consent.
Exclusion: Daily use of any form of steroid medication (oral, inhaled, injected) within the last 3 months; Presence of type 1 or type 2 diabetes; Active cardiovascular diseases within 12 months of Visit 1, such as myocardial infarction, clinically significant arrhythmia, unstable angina, coronary artery bypass surgery, or angioplasty; or are expected to require coronary artery bypass surgery or angioplasty during the course of the study; Endocrine disorders (e.g., Itsenko-Cushing syndrome, acromegaly) that affect glycemia; Known allergy to sensor materials; Has evidence of current abuse of drugs or alcohol or a history of abuse that, in the investigator's opinion, would cause the individual to be noncompliant; Decompensated liver or kidney diseases (GFR < 45 ml/min/1. 73 m²); Pregnancy or lactation; Mental or cognitive impairments that would interfere with study participation; Recent use of any CGM within the last 12 months; Participation in another clinical study within the last 3 months.